Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

But Eli Lilly's supply woes began to ease earlier this year, and the Food and Drug Administration removed tirzepatide, the active ingredient in Mounjaro and Zepbound, from its shortage list.

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from ...

This might have boosted Zepbound sales in the quarter. Lilly’s tirzepatide medicines face strong competition from Novo Nordisk ’s NVO semaglutide.

As demand soars for weight loss medications, so has the competition. Eli Lilly slashed prices for its hugely successful obesity medication, Zepbound. This comes at a time when compounded GLP-1 ...

Drugs like Lilly's Zepbound and Mounjaro, along with Novo Nordisk's Ozempic and Wegovy, known as GLP-1 receptor agonists, are already being put to use for obesity and diabetes.

Despite its pricey valuation, I still see Eli Lilly as an extremely compelling opportunity for long-term investors. Both Mounjaro and Zepbound are already blockbuster drugs.

Eli Lilly's drug candidate tirzepatide was approved yesterday to treat obesity, under the brand name Zepbound. See if LLY stock's valuation can grow higher.